Incidence and outcome of invasive fungal infections in pediatric patients with hematological malignancies and/or undergoing allogeneic hematopoietic stem cell transplantation – a prospective analysis in three major pediatric cancer centers (IFI-PED Study)”
Recruiting
- Conditions
- Children with hematological malignancy (C91.0C92.0)/children undergoing hematopoietic stem cell transplantationproven, probable, and possible invasive fungal infection (B49)B49C92.0C91.0Unspecified mycosisAcute myeloblastic leukaemia [AML]Acute lymphoblastic leukaemia [ALL]
- Registration Number
- DRKS00006341
- Lead Sponsor
- Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
• Children and adolescents 0 to <18 years who are diagnosed with acute lymphoblastic leukemia, acute myeloid leukemia, relapse of acute leukemia or receive an allogeneic hematopoietic stem cell transplantation in the University Children´s Hospitals of Frankfurt, Münster or in St. Anna Kinderspital, Vienna, respectively
• Diagnosis of the malignancy/ transplantation between April 1, 2014 and March 31, 2016
• Written informed consent is mandatory for enrollment in the study.
Exclusion Criteria
• Patients without written informed will be excluded from the study.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to describe the epidemiology of invasive fungal infections in three major pediatric cancer centers in Germany/Austria<br>
- Secondary Outcome Measures
Name Time Method 1) to characterize risk factors and periods of risk for invasive fungal infections in different pediatric patient populations (e.g., children suffering from ALL, AML etc) <br>2) outcome of invasive fungal infections in pediatric cancer patients